The research company Pharmalundensis intends to raise 6 million dollars from international investors to finance GMP production of Phal-501 as well as clinical studies in KOL and chronic fatigue syndrome, according to a press release. The company has at the same time presented a business plan to be used in dialogue with investors ahead of the capital raise.